KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Convertible Debt: 2010-2011

  • Nektar Therapeutics' Convertible Debt was N/A to $215.0 million in Q2 2011 from the same period last year, while for Jun 2011 it was $215.0 million, marking a year-over-year change of. This contributed to the annual value of $215.0 million for FY2010, which is N/A change from last year.
  • Latest data reveals that Nektar Therapeutics reported Convertible Debt of $215.0 million as of Q2 2011, which was down 0.00% from $215.0 million recorded in Q1 2011.
  • Nektar Therapeutics' Convertible Debt's 5-year high stood at $215.0 million during Q4 2010, with a 5-year trough of $215.0 million in Q4 2010.
  • In the last 2 years, Nektar Therapeutics' Convertible Debt had a median value of $215.0 million in 2011 and averaged $215.0 million.